哌拉西林钠舒巴坦钠治疗重症肺部感染患者的临床疗效及其安全性  

Clinical Efficacy and Safety of Piperacillin Sodium and Sulbactam in the Treatment of Patients with Severe Pulmonary Infection

作　　者：魏慎霞 刘华田 周思齐 WEI Shenxia;LIU Huatian;ZHOU Siqi(Emergency Department,Xuzhou New Health Hospital,Xuzhou,Jiangsu,221000,China;Department of Neurosurgery,Xuzhou New Health Hospital,Xuzhou,Jiangsu,221000,China)

机构地区：[1]徐州新健康医院急诊科,江苏徐州221000 [2]徐州新健康医院神经外科,江苏徐州221000

出　　处：《中外医疗》2025年第8期65-69,共5页China & Foreign Medical Treatment

摘　　要：目的重症肺部感染患者联合哌拉西林钠舒巴坦钠治疗,观察其临床疗效并评估用药安全性。方法方便选取2022年1月—2024年1月徐州新健康医院收治的78例重症肺部感染患者,分组方式根据不同治疗方法,即对照组(39例)和研究组(39例)。对照组的治疗方式为左氧氟沙星,研究组的治疗方式为左氧氟沙星联合哌拉西林钠舒巴坦钠。对比两组患者的临床相关指标、血清炎症因子水平、肺部感染情况及不良反应发生情况。结果相较于对照组,研究组体温恢复时间、肺部湿啰音消失时间、机械通气时间均更短,排痰量更多,差异均有统计学意义(P均<0.05)。治疗后,相较于治疗前,两组血清炎症因子水平更低,相较于对照组,研究组血清炎症因子水平更低,差异均有统计学意义(P均<0.05)。治疗后,相较于对照组(6.46±0.92)分,研究组临床肺部感染评分(5.38±0.75)分更低,差异有统计学意义(t=5.682,P<0.05)。两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论在左氧氟沙星治疗基础上为重症肺部感染患者应用哌拉西林钠舒巴坦钠治疗效果较好,优于单纯应用左氧氟沙星治疗,可缩短症状缓解时间、提升排痰效率、降低炎性因子水平和肺部感染评分,且安全性高,不良反应较少。Objective To observe the clinical efficacy and evaluate the safety of piperacillin sodium and sulbactam in patients with severe pulmonary infection.Methods Conveniently select 78 patients with severe pulmonary infections admitted to Xuzhou New Health Hospital from January 2022 to January 2024,and group them according to different treatment methods,namely the control group(39 cases)and the study group(39 cases).The treatment for the control group was levofloxacin,while the treatment for the study group was levofloxacin combined with piperacillin sodium and sulbactam sodium.The clinical related indexes,serum inflammatory factor levels,pulmonary infection and adverse reactions were compared between the two groups.Results Compared to the control group,the study group had a shorter time for body temperature recovery,disappearance of wet rales in the lungs,and mechanical ventilation,as well as a higher sputum output,the differences were statistically significant(all P<0.05).After treatment,compared with before treatment,the levels of serum inflammatory factors in both groups were lower,compared with the control group,the levels of serum inflammatory factors in the study group were lower,the differences were statistically significant(all P<0.05).After treatment,compared to the control group(6.46±0.92),the clinical pulmonary infection score of the study group(5.38±0.75)was lower,and the difference was statistically significant(t=5.682,P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion On the basis of levofloxacin treatment,piperacillin sodium and sulbactam is effective in the treatment of patients with severe pulmonary infection,which is better than levofloxacin alone.It can shorten the time of symptom relief,improve the efficiency of expectoration,reduce the level of inflammatory factors and the score of pulmonary infection,and has high safety and less adverse reactions.

关 键 词：哌拉西林钠舒巴坦 左氧氟沙星 重症肺部感染 临床疗效 炎症因子 安全性 

分 类 号：R56[医药卫生—呼吸系统]